KZIA
Kazia Therapeutics LimitedNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.71
P/S
872.10
EV/EBITDA
2.87
DCF Value
$-0.66
FCF Yield
-52.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-92086.4%
Net Margin
-113004.6%
ROE
-116.9%
ROA
-31.4%
ROIC
-36.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-12.3M | $-3.95 |
| Q4 2025 | $19.7K | $-10.0M | $-6.40 |
| FY 2025 | $42.0K | $-20.7M | $-18.90 |
| Q2 2025 | $22.3K | $-10.5M | $-6.15 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
AU
Exchange
NASDAQ
Beta
1.62
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.